



**PHARMACY AND THERAPEUTICS COMMITTEE
ACA/Exchange MEETING MINUTES
May 14, 2026**

*Attendance: Microsoft Teams Meeting
Gary Bledsoe, Staff/Clinical Pharmacist; Connie Chan, Staff/Clinical Pharmacist; Dr. Edgar Chou, Jefferson Health; Jerry Crawford, Staff/Clinical Pharmacist; Kristen DeSorte, Staff/Clinical Pharmacist; Danielle Dolores, Director Pharmacy Services; Dr. George E. Downs, Dean Emeritus and Professor, St. Joseph’s University; Leah Finken, Clinical Programs Pharmacist; Sharon Ford, Staff/Clinical Pharmacist; Paul Goebel, Assistant Director Pharmacy, Jefferson Enterprise; Dr. Merleen Harris-Williams, Medical Director; Gia Ho, Pharmacy Resident; Samantha Jackson, Formulary Pharmacist; Ruth John, Staff/Clinical Pharmacist; Lawrence Jones, Retired Executive Director, Pennsylvania Society of Health-System Pharmacists (PSHP); Sheenu Joseph, Staff/Clinical Pharmacist; Kaylei Koerwitz, Manager Pharmacy Operations and Clinical Programs; Dr. Tania Kolev, Medical Director; Brandi Mahler, Supervisor Pharmacy Technicians; Hannah McCaffrey, Manager Pharmacy Regulations & Implementations; Michele McKenna, Staff/Clinical Pharmacist; Lisa Murray, Staff/Clinical Pharmacist; Claudia Pinketti, Staff/Clinical Pharmacist; Ryan Prager, Staff/Clinical Pharmacist; Maryana Prokopets, Staff/Clinical Pharmacist; Kateryna Puia, Clinical Programs Pharmacist; Sanjiv Raj, Associate VP Customer Engagement; Sara Sadiq, Staff/Clinical Pharmacist; Heather Scheckner, Clinical Pharmacist, Jefferson Health; Mike Smikovecus, Staff/Clinical Pharmacist; Robert Spencer, Staff/Clinical Pharmacist; Shelley Staffa, Clinical Pharmacist; Justin Steffan, Staff/Clinical Pharmacist; Tara Swartz, Staff/Clinical Pharmacist; Fallan Vaisberg, Formulary Pharmacist; Jeanine Zubrzycki, Staff/Clinical Pharmacist*

Excused: Dr. Paul Aitken, Medical Director; Dr. Neal Demp, Community Behavior Health; Dr. Demian Elder, Medical Director; Hailey Fry, Centennial Pharmacy; Yelena Hedrick, Staff/Clinical Pharmacist; Jessica Hoang-Le, Staff/Clinical Pharmacist; Julie Samuel, Clinical Programs Pharmacist; Dr. Chris Squillaro, Medical Director, Magellan Behavioral Health

Minutes taken by: Joana Iverson

I. Administrative Update

TOPIC	DISCUSSION	ACTIONS	RESPONSIBLE PARTY	RESOLVED/PENDING
<i>Minutes Review/Approval</i>	<i>D. Dolores presented the minutes from the February 2026 meeting to the Committee for review.</i>	<i>The Committee approved the minutes from our last meeting as presented.</i>	<i>D. Dolores</i>	<i>Resolved</i>

II. 2027 Formulary Updates

TOPIC	DISCUSSION	ACTIONS	RESPONSIBLE PARTY	RESOLVED/PENDING
<p>2027 Formulary Additions</p>	<p>The Committee reviewed the 2027 Formulary Additions. The Committee approved as presented.</p> <ul style="list-style-type: none"> • Adalimumab-adbm - T5, PA • Adalimumab-ryvk - T5, PA • Baqsimi - T3 • Bildyos - T4, PA • Bilprevda - T5, PA • Bimatoprost 0.01% - T2 • Eltrombopag tablets, powder for suspension - T5, PA • Enoby - T4, PA • Imuldosa - T5, PA • Kloxxado - T3 • Miebo - T3, QL • Osenvelt - T5, PA • Selarsdi - T5, PA • Simlandi - T5, PA • Ustekinumab-ttwe - T5, PA • Xdemvy - T5, PA • Xtrenbo - T5, PA • Yesintek - T5, PA • Yeztugo tablet, injection - T0 	<p>The Committee approved as presented.</p>	<p>F. Vaisberg</p>	<p>Resolved</p>
<p>2027 Formulary Removals</p>	<p>The Committee reviewed the 2027 Formulary Removals.</p> <ul style="list-style-type: none"> • Sofosbuvir/velpatasvir - Epclusa preferred • Ledipasvir/sofosbuvir -Harvoni preferred • Anucort-HC • Anusol HC • Atrovent - Generic added • Besivance - Generic added • Briviact - Generic added • Clenpiq -Generics preferred • Farxiga - Generic added • Gleostine - Generic added • Humira - Biosimilar added • Hyrimoz - New biosimilar added • Lumigan - Generic added • Mavyret • Nitro-Bid - Generic added • Nucynta 	<p>The Committee approved as presented.</p>	<p>F. Vaisberg</p>	<p>Resolved</p>

TOPIC	DISCUSSION	ACTIONS	RESPONSIBLE PARTY	RESOLVED/PENDING
	<ul style="list-style-type: none"> • <i>Ofev - Generic added</i> • <i>Pomalyst - Generic added</i> • <i>Premarin - Generic added</i> • <i>Prolia - Biosimilar added</i> • <i>Regranex - Product discontinued</i> • <i>Repatha Pushtronex - Product discontinued</i> • <i>Savella - Generic added</i> • <i>Sovaldi</i> • <i>Spiriva Handihaler - Spiriva Respimat preferred</i> • <i>Stelara - Biosimilars added</i> • <i>Tracleer 32 mg tablet - Generic added</i> • <i>Xigduo - Generic added</i> • <i>Zylet - Generic added</i> 			
2027 Tier Changes	<p><i>The Committee reviewed the 2027 Tier Changes.</i></p> <ul style="list-style-type: none"> • <i>Dapagliflozin 5 MG tab - Move to T2</i> • <i>Dapagliflozin 10 MG tab - Move to T2</i> • <i>Dapagliflozin base-metformin ER 5-500 MG tab - Move to T2</i> • <i>Dapaglifloz base-metformin ER 10-500 MG tab - Move to T2</i> • <i>Dapaglifloz base-metformin ER 5-1000 MG tab - Move to T2</i> • <i>Dapaglifloz base-metformin ER 10-1000 MG tab - Move to T2</i> 	<i>The Committee approved as presented.</i>	<i>F. Vaisberg</i>	<i>Resolved</i>

III. 2027 Prior Authorization Review/Update

2027 Prior Authorization Criteria Review	<p><i>The Committee reviewed the 2027 Prior Authorization Criteria. The Committee approved as presented.</i></p> <ul style="list-style-type: none"> • <i>Austedo/ Austedo XR</i> • <i>Tetrabenazine</i> 	<i>The Committee approved as presented.</i>	<i>F. Vaisberg</i>	<i>Resolved</i>
---	---	---	--------------------	-----------------

IV. 2026 Formulary Updates

2026 Formulary Additions	<p><i>The Committee reviewed the Formulary Additions. The Committee approved as presented.</i></p> <ul style="list-style-type: none"> • <i>Dapagliflozin tablet - T3, QL 30/30 days</i> • <i>Dapaglifloz base-metformin ER 5-500 mg - T3, QL 60/30 days</i> • <i>Dapaglifloz base-metformin ER 5-1000 mg - T3, QL 60/30 days</i> 	<i>The Committee approved as presented.</i>	<i>F. Vaisberg</i>	<i>Resolved</i>
---------------------------------	---	---	--------------------	-----------------

	<ul style="list-style-type: none"> • <i>Dapaglifloz base-metformin ER 10-500 mg - T3, QL 30/30 days</i> • <i>Dapaglifloz base-metformin ER 10-1000 mg - T3, QL 30/30 days</i> • <i>Lomustine capsule - T3, PA</i> • <i>Milnacipran tablet - T4, QL 60/30 days, ST</i> • <i>Nintedanib esylate capsule - T5, PA, QL 60/30 days</i> • <i>Nitroglycerin 2 % ointment - T3</i> • <i>Pomalidomide capsule - T5, PA, QL 21/28 days</i> • <i>Rilpivirine tablet - T3, QL 30/30 days</i> 			
2026 Formulary Removals	<p><i>The Committee reviewed the 2026 Formulary Removals and approved as presented.</i></p> <ul style="list-style-type: none"> • <i>Farxiga - NF (effective 9/1/26)</i> • <i>Xigduo XR - NF (effective 9/1/26)</i> • <i>Humira - NF (effective 9/1/26)</i> • <i>Stelara - NF (effective 9/1/26)</i> 	<i>The Committee approved as presented.</i>	<i>F. Vaisberg</i>	<i>Resolved</i>
V. New Drug Review	<p><i>(Presented in New Drug Review for Medicare.)</i></p> <p><i>The following new Protected Class Drugs were reviewed and will be added to the formulary per CMS regulations:</i></p> <ul style="list-style-type: none"> • <i>Tecartus (brexucabtagene autoleucl) Suspension for Intravenous Infusion</i> • <i>Lifyorli (relacorilant) Capsules*</i> • <i>Adstiladrin (nadofaragene firadenovec-vncg) Suspension for Intravesical Use</i> • <i>Opdivo (nivolumab) Injection</i> • <i>Tecvayli (teclistamab-cqyv) Injection</i> • <i>Hernexeos (zongertinib) Tablets</i> • <i>Braftovi (encorafenib) Capsules</i> • <i>Bysanti (milsaperidone) Tablets*</i> • <i>Calquence (acalabrutinib) Capsules and Tablets</i> • <i>Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) Injection</i> <p><i>The following medications are Formulary with new FDA-approved indications:</i></p> <ul style="list-style-type: none"> • <i>Arexvy (respiratory syncytial virus vaccine, adjuvanted) Suspension for Intramuscular Injection</i> • <i>Sotyktu (deucravacitinib) Tablets</i> • <i>Dupixent (dupilumab) Injection</i> <p><i>The following medications were reviewed and will be kept as Non-formulary. Prior Authorization criteria will be developed as needed:</i></p> <ul style="list-style-type: none"> • <i>Eylea HD (aflibercept) Injection</i> 	<i>The Committee approved as presented and recommended.</i>	<i>G. Ho</i>	<i>Resolved</i>

	<ul style="list-style-type: none"> • <i>Foundayo (orforglipron) Tablets*</i> • <i>Ponlimsi (denosumab-adet) Injection*</i> • <i>Spinraza (nusinersen) Injection</i> • <i>Alyftrek (deutivacaftor, tezacaftor and vanzacaftor) Tablets</i> • <i>Neffy (epinephrine) Nasal Spray</i> • <i>Awikli (insulin icodec-abae) Injection*</i> • <i>Kresladi (marnetegrane autotemcel) Suspension for Intravenous Infusion*</i> • <i>Avlayah (tvidenofusp alfa-eknm) Lyophilized Powder for Injection*</i> • <i>Imcivree (setmelanotide) Injection</i> • <i>Wegovy (semaglutide) Injection</i> • <i>Lynavoy (linerixibat) Tablets*</i> • <i>Icotyde (icotrokinra) Tablets*</i> • <i>Cosentyx (secukinumab) Injection</i> • <i>Wellcovorin (leucovorin calcium) Tablets</i> • <i>Pylarify (piflufolostat F18) Injection</i> • <i>Sogroya (somapacitan-beco) Injection</i> • <i>Palynziq (pegvaliase-pqpz) Injection</i> • <i>Yuviwel (navepegritide) Lyophilized Powder for Injection - formerly TransCon CNP*</i> • <i>Juxtapid (lomitapide) Capsules</i> • <i>Desmoda (desmopressin acetate) Oral Solution - formerly ET-600*</i> • <i>Loargys (pegzilarginase-nbln) Injection*</i> • <i>Elucirem (gadopiclenol) Injection</i> • <i>Wakix (pitolisant) Tablets</i> • <i>Adquey (difamilast) Ointment*</i> • <i>Enzeevu (aflibercept-abzv) Injection</i> • <i>Zepbound (tirzepatide) Injection</i> <p>(* Previously discussed in New Drug Review for Medicaid)</p>			
--	---	--	--	--

VI. Adjournment

There being no further business to discuss, the meeting was adjourned. Next meeting is to be held August 2026.



5/27/2026

Danielle Dolores, Director of Pharmacy Services

Date